<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">101724</article-id><article-id pub-id-type="doi">10.7554/eLife.101724</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.101724.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Cao</surname><given-names>Feilin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0002-5083-1462</contrib-id><email>drcfl@126.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ma</surname><given-names>Zhaosheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Zenggui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Weizhu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ouchen</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cui</surname><given-names>Binbin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhu</surname><given-names>Xiaotao</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hao</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib3">§</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ji</surname><given-names>Xiaochun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib3">§</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Zhanwen</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="equal-contrib3">§</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Deyou</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Feng</surname><given-names>Qingjing</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="equal-contrib4">#</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lin</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="equal-contrib4">#</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shi</surname><given-names>Dongbo</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="equal-contrib4">#</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shu</surname><given-names>Jingde</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="equal-contrib4">#</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Jichun</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Shifen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05m0wv206</institution-id><institution>Department of Thyroid and Breast Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Taizhou</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/030zcqn97</institution-id><institution>Department of Thyroid and Breast Surgery, Ningbo Medical Center Lihuili Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Ningbo</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cyvdv85</institution-id><institution>Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Wenzhou</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04z13ha89</institution-id><institution>Department of Thyroid and Breast Surgery, Jinhua Municipal Central Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Jinhua</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04z13ha89</institution-id><institution>Department of Thyroid and Breast Surgery, Yiwu Central Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Jinhua</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution>Department of Breast Surgery, Ningbo Women and Children's Hospital</institution><addr-line><named-content content-type="city">Ningbo</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution>Department of Breast Surgery, Yiwu Maternity and Children Hospital</institution><addr-line><named-content content-type="city">Jinhua</named-content></addr-line><country>China</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/004qehs09</institution-id><institution>Department of Surgical Oncology, Quzhou People's Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Quzhou</named-content></addr-line><country>China</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03et85d35</institution-id><institution>Department of Breast Surgery, The First Affiliated Hospital of Ningbo University</institution></institution-wrap><addr-line><named-content content-type="city">Ningbo</named-content></addr-line><country>China</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ka6rp58</institution-id><institution>Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zhao</surname><given-names>Yu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02drdmm93</institution-id><institution>Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib2"><label>‡</label><p>These authors also contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib3"><label>§</label><p>These authors also contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib4"><label>#</label><p>These authors also contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>04</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP101724</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-09-05"><day>05</day><month>09</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-09-05"><day>05</day><month>09</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.09.05.24313095"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-09"><day>09</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101724.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-02-28"><day>28</day><month>02</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101724.2"/></event></pub-history><permissions><copyright-statement>© 2024, Cao, Ma, Wu et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Cao, Ma, Wu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-101724-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Approximately one-third of patients with HER2-positive breast cancer experienced recurrence within 10 years after receiving 1 year of adjuvant trastuzumab. The ExteNET study showed that 1 year of extended adjuvant neratinib after trastuzumab-based adjuvant therapy could reduce invasive disease-free survival (iDFS) events compared with placebo. This study investigated the efficacy and safety of pyrotinib, an irreversible pan-HER receptor tyrosine kinase inhibitor, after trastuzumab-based adjuvant therapy in patients with high-risk, HER2-positive early or locally advanced breast cancer.</p></sec><sec id="abs2"><title>Methods:</title><p>This multicenter phase II trial was conducted at 23 centers in China. After enrollment, patients received 1 year of extended adjuvant pyrotinib (400 mg/day), which should be initiated within 6 months after the completion of 1-year adjuvant therapy (trastuzumab alone or plus pertuzumab). The primary endpoint was 2-year iDFS rate.</p></sec><sec id="abs3"><title>Results:</title><p>Between January 2019 and February 2022, 141 eligible women were enrolled and treated. As of October 10, 2022, the median follow-up was 24 (interquartile range, 18.0–34.0) months. The 2-year iDFS rate was 94.59% (95% confidence interval [CI]: 88.97–97.38) in all patients, 94.90% (95% CI: 86.97–98.06) in patients who completed 1-year treatment, 90.32% (95% CI: 72.93–96.77) in patients who completed only 6-month treatment, 96.74% (95% CI: 87.57–99.18) in the hormone receptor (HR)-positive subgroup, 92.77% (95% CI: 83.48–96.93) in the HR-negative subgroup, 96.88% (95% CI: 79.82–99.55) in the lymph node-negative subgroup, 93.85% (95% CI: 86.81–97.20) in the lymph node-positive subgroup, 97.30% (95% CI: 82.32–99.61) in patients with adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06–97.02) in patients with adjuvant trastuzumab. The most common adverse events were diarrhea (79.4%), fatigue (36.9%), lymphocyte count decreased (36.9%), nausea (33.3%), and hand-foot syndrome (33.3%).</p></sec><sec id="abs4"><title>Conclusions:</title><p>Extended adjuvant pyrotinib administrated after trastuzumab-based adjuvant therapy showed promising efficacy in patients with high-risk HER2-positive breast cancer. The follow-up is ongoing to determine the long-term benefit.</p></sec><sec id="abs5"><title>Funding:</title><p>No external funding was received for this work.</p></sec><sec id="abs6"><title>Clinical trial number:</title><p>ClinicalTrials.gov: <related-object id="RO1" source-type="clinical-trials-registry" source-id-type="registry-name" source-id="ClinicalTrials.gov" document-id="NCT05880927" document-id-type="clinical-trial-number" xlink:href="https://clinicaltrials.gov/show/NCT05880927">NCT05880927</related-object></p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>breast cancer</kwd><kwd>pyrotinib</kwd><kwd>human epidermal growth factor receptor 2</kwd><kwd>extended adjuvant therapy</kwd><kwd>invasive disease-free survival</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Kaplan–Meier curves showed that extended adjuvant pyrotinib administered after trastuzumab-based adjuvant therapy provides a promising survival benefit in patients with high-risk HER2-positive breast cancer.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Worldwide, breast cancer is the most commonly diagnosed malignancy in women. Approximately 15–20% of breast cancer cases are characterized by the overexpression of human epidermal growth factor receptor 2 (HER2) (<xref ref-type="bibr" rid="bib24">Siegel et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Loibl and Gianni, 2017</xref>). Over the past 20 years, with the emergence of HER2-targeted agents, it has been proved that the addition of 1-year trastuzumab to adjuvant chemotherapy significantly reduces the recurrence rate and prolongs survival in patients with HER2-positive breast cancer (<xref ref-type="bibr" rid="bib19">Perez et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Cameron et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Wolff et al., 2013</xref>). However, the phase III HERA study found that, despite receiving 1 year of adjuvant trastuzumab, 31% of patients with HER2-positive breast cancer experienced recurrence within 10 years (<xref ref-type="bibr" rid="bib4">Cameron et al., 2017</xref>). In addition, the phase III APHINITY study reported a 12% recurrence rate in HER2-positive breast cancer patients with node-positive disease after receiving 1 year of adjuvant trastuzumab, pertuzumab, and chemotherapy with a median follow-up of 74 months (<xref ref-type="bibr" rid="bib20">Piccart et al., 2021</xref>). Consequently, novel treatment approaches are warranted to extend the time to recurrence.</p><p>Currently, the efficacy of extended adjuvant therapy has only been investigated in the phase III ExteNET study. The results showed that 1 year of neratinib after trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (iDFS) in women with HER2-positive breast cancer. However, the iDFS benefit did not translate into overall survival benefit in the intention-to-treat population after 8-year follow-up, except for patients with hormone receptor (HR)-positive disease (<xref ref-type="bibr" rid="bib9">Holmes et al., 2023</xref>; <xref ref-type="bibr" rid="bib13">Lüftner et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Martin et al., 2017</xref>).</p><p>Pyrotinib is an oral irreversible pan-HER receptor tyrosine kinase inhibitor (TKI), targeting epidermal growth factor receptor, HER2, and HER4 (<xref ref-type="bibr" rid="bib14">Ma et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Guan et al., 2023b</xref>; <xref ref-type="bibr" rid="bib30">Xu et al., 2021</xref>). For patients with HER2-positive metastatic breast cancer, improved survival outcomes were shown in the pyrotinib group when compared with the control group in the phase III PHOEBE and PHILA studies (<xref ref-type="bibr" rid="bib15">Ma et al., 2023</xref>; <xref ref-type="bibr" rid="bib29">Wu et al., 2022</xref>). Additionally, results from the phase III PHEDRA trial demonstrated clinical benefits of pyrotinib plus trastuzumab and docetaxel for patients with HER2-positive early or locally advanced breast cancer in the neoadjuvant setting (<xref ref-type="bibr" rid="bib5">Chan et al., 2016</xref>).</p><p>In the present PERSIST study, our objective was to assess the efficacy and safety of administering extended adjuvant pyrotinib treatment following trastuzumab-based adjuvant therapy in patients with high-risk, HER2-positive early or locally advanced breast cancer. This report presents the efficacy and safety results with a median follow-up of 2 years, while longer follow-up is still ongoing.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study design and participants</title><p>This multicenter, single-arm, investigator-initiated, phase II exploratory study was conducted at 23 sites in China. The study protocol was approved by the institutional ethics committee of Taizhou Hospital of Zhejiang Province and all other participating centers, and the trial was performed in accordance with the 2013 Declaration of Helsinki. This trial was registered at <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> (NCT05880927). Written informed consent was obtained from all patients before study enrollment.</p><p>Participants were eligible if they were women aged 18–75 years with high-risk, HER2-positive (immunohistochemistry 3+, or 2+ with gene amplification by fluorescence in situ hybridization) early or locally advanced invasive breast cancer; had previously completed 1 year of adjuvant therapy with either trastuzumab or trastuzumab plus pertuzumab within 6 months before enrollment; had an Eastern Cooperative Oncology Group performance status of 0 or 1; had known HR status; and had adequate bone marrow, hepatic, renal, and cardiac functions.</p><p>High-risk patients were defined as those meeting one of the following criteria: N stage ≥1; T stage ≥2; absence of pathological complete response (pCR) after neoadjuvant therapy; presence of pCR after neoadjuvant therapy but with tumor size ≥5 cm or N stage ≥2; tumor size &lt;2 cm but with high Ki-67 level or histologic grade 3. Clinical and pathological stage was assessed according to the eighth edition of American Joint Committee on Cancer tumor-node-metastasis staging system. The expression of Ki-67 was categorized as low (&lt;20%) and high (≥20%) based on the ratio of positive cells to all tumor cells in 10 high-power fields.</p><p>The main exclusion criteria were bilateral breast cancer, inflammatory breast cancer, previous participation in other clinical trials involving anticancer therapy, allergies to the drug components in this protocol, history of immunodeficiency diseases, inability to swallow, and pregnancy or lactation.</p></sec><sec id="s2-2"><title>Procedure</title><p>Pyrotinib 400 mg was administrated orally once daily within 6 months of completing trastuzumab-based adjuvant therapy. Concurrent adjuvant endocrine therapy for HR-positive disease was recommended.</p><p>Treatment duration was 12 months unless intolerable adverse events, disease recurrence, death, or consent withdrawal occurred.</p></sec><sec id="s2-3"><title>Outcomes and assessment</title><p>The primary endpoint was iDFS rate at 2 years. IDFS was defined as time from the initiation of pyrotinib treatment to invasive ipsilateral tumor recurrence, invasive contralateral breast cancer, local or regional invasive recurrence, distant recurrence, or death from any cause. The secondary endpoint was safety profile, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.</p><p>Patients were followed every 3 months for the first 2 years. The follow-up assessments included physical examination, Eastern Cooperative Oncology Group performance status, complete blood count, blood chemistry analysis, 12-lead electro-cardiogram, recording of adverse events, concomitant medications, and ultrasound. Computed tomography and bone scans may be conducted if clinically indicated.</p></sec><sec id="s2-4"><title>Statistical analysis</title><p>Based on the previous ExteNET trial (<xref ref-type="bibr" rid="bib3">Burstein et al., 2021</xref>), the 2-year iDFS rate was assumed as 91% in the present study. To restrain the width of 2-sided 95% confidence interval (CI) to no more than 0.1, 126 patients were required. Considering a dropout rate of 10%, a total of 140 participants were recruited.</p><p>Continuous data were presented as median (range or interquartile range), while categorical data were presented as frequency (percentage). IDFS was estimated using the Kaplan–Meier method, and the corresponding 95% CI was estimated using the Brookmeyer–Crowley method. Efficacy analysis was performed in the full analysis set, which included all patients who received at least one dose of study drug. Safety analysis was performed in the safety set, defined as all patients who received at least one dose of the study drug and underwent at least one safety assessment.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Baseline characteristics</title><p>Between January 2019 and February 2022, a total of 141 eligible women were enrolled in the study and received pyrotinib. All these patients were included in the full analysis set and safety set. The median age was 50 years (range, 25–72). Of the 141 patients, 107 (75.9%) patients had node-positive disease, and 64 (45.4%) had HR-positive disease. Detailed baseline characteristics are summarized in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Baseline characteristics of patients in the full analysis set.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variables</th><th align="left" valign="bottom">All (<italic>n</italic> = 141)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Age (years), median (range</bold>)</td><td align="left" valign="bottom">50 (25–72)</td></tr><tr><td align="left" valign="bottom"><bold>T stage, <italic>n</italic> (%)</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">T1</td><td align="left" valign="bottom">43 (30.5%)</td></tr><tr><td align="left" valign="bottom">T2</td><td align="left" valign="bottom">83 (58.9%)</td></tr><tr><td align="left" valign="bottom">T3</td><td align="left" valign="bottom">11 (7.8%)</td></tr><tr><td align="left" valign="bottom">T4</td><td align="left" valign="bottom">2 (1.4%)</td></tr><tr><td align="left" valign="bottom">Unable to determine</td><td align="left" valign="bottom">2 (1.4%)</td></tr><tr><td align="left" valign="bottom"><bold>Nodal status, <italic>n</italic> (%)</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Negative</td><td align="left" valign="bottom">34 (24.1%)</td></tr><tr><td align="left" valign="bottom">1–3 positive nodes</td><td align="left" valign="bottom">49 (34.8%)</td></tr><tr><td align="left" valign="bottom">&gt;3 positive nodes</td><td align="left" valign="bottom">58 (41.1%)</td></tr><tr><td align="left" valign="bottom"><bold>Hormone receptor status, <italic>n</italic> (%)</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Negative (ER and PR negative)</td><td align="left" valign="bottom">77 (54.6%)</td></tr><tr><td align="left" valign="bottom">Positive (ER positive, PR positive, or both)</td><td align="left" valign="bottom">64 (45.4%)</td></tr><tr><td align="left" valign="bottom"><bold>Ki-67, <italic>n</italic> (%)</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">≥20%</td><td align="left" valign="bottom">119 (84.4%)</td></tr><tr><td align="left" valign="bottom">&lt;20%</td><td align="left" valign="bottom">22 (15.6%)</td></tr><tr><td align="left" valign="bottom"><bold>Previous neoadjuvant therapy, <italic>n</italic> (%)</bold></td><td align="left" valign="bottom">26 (17.7%)</td></tr><tr><td align="left" valign="bottom"><bold>Previous adjuvant therapy, <italic>n</italic> (%)</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Trastuzumab</td><td align="left" valign="bottom">92 (65.2%)</td></tr><tr><td align="left" valign="bottom">Trastuzumab plus pertuzumab</td><td align="left" valign="bottom">49 (34.8%)</td></tr></tbody></table><table-wrap-foot><fn><p>Tumors were assessed as being ER or PR positive with a threshold of 1%.</p></fn><fn><p>ER, estrogen receptor; PR, progesterone receptor.</p></fn></table-wrap-foot></table-wrap><p>In terms of treatment duration, 11 patients discontinued their treatment due to adverse events, while 38 patients had a treatment duration of less than or equal to 6 months due to the COVID-19 pandemic or personal reasons. A total of 92 and 31 patients completed 1-year and 6-month treatment of extended adjuvant pyrotinib, respectively (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Study flowchart.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101724-fig1-v1.tif"/></fig><sec id="s3-1-1"><title>Efficacy</title><p>As of October 10, 2022, the median follow-up duration was 24 (interquartile range, 18.0–34.0) months. Of the 141 patients, seven patients experienced iDFS events, including one local recurrence, three brain metastases, two lung metastases, and one death due to distant metastasis. The 2-year iDFS rate was 94.59% (95% CI: 88.97–97.38; <xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Kaplan–Meier estimates of invasive disease-free survival in the full analysis set.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101724-fig2-v1.tif"/></fig><p>Subgroup analyses showed that the 2-year iDFS rate was 94.90% (95% CI: 86.97–98.06) in the 1-year treatment subgroup and 90.32% (95% CI: 72.93–96.77) in the 6-month treatment subgroup (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Concerning HR status, the 2-year iDFS rate was 96.74% (95% CI: 87.57–99.18) in patients with HR-positive breast cancer and 92.77% (95% CI: 83.48–96.93) in patients with HR-negative breast cancer (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). In terms of lymph node status, the 2-year iDFS rate was 96.88% (95% CI: 79.82–99.55) in patients with lymph node-negative breast cancer and 93.85% (95% CI: 86.81–97.20) in patients with lymph node-positive breast cancer (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Regarding trastuzumab-based adjuvant regimen, the 2-year iDFS rate was 97.30% (95% CI: 82.32–99.61) in patients who received adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06–97.02) in patients who received adjuvant trastuzumab (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Invasive disease-free survival in different subgroups.</title><p>Kaplan–Meier curves for invasive disease-free survival in (<bold>A</bold>) patients who received 6-month (<italic>n</italic> = 31) and 1-year pyrotinib treatment (<italic>n</italic> = 92), (<bold>B</bold>) patients with hormone receptor-positive breast cancer (<italic>n</italic> = 64) and hormone receptor-negative breast cancer (<italic>n</italic> = 77), (<bold>C</bold>) patients with lymph node-positive breast cancer (<italic>n</italic> = 107) and patients with lymph node-negative breast cancer (<italic>n</italic> = 34), and (<bold>D</bold>) patients who received adjuvant therapy with trastuzumab (<italic>n</italic> = 92) and trastuzumab plus pertuzumab (<italic>n</italic> = 49).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101724-fig3-v1.tif"/></fig></sec><sec id="s3-1-2"><title>Safety</title><p>The most frequently reported treatment-emergent adverse event was diarrhea (112 [79.4%]), followed by fatigue (52 [36.9%]), lymphocyte count decreased (52 [36.9%]), nausea (47 [33.3%]), and hand-foot syndrome (47 [33.3%]). Forty-three patients (30.5%) experienced grade 3 diarrhea, while no grade 4 or higher adverse events was reported (<xref ref-type="table" rid="table2">Table 2</xref>). Treatment discontinuation occurred in 11 (7.8%) patients, due to grade 3 diarrhea (<italic>n</italic> = 8), grade 3 hand-foot syndrome (<italic>n</italic> = 1), and intolerance (<italic>n</italic> = 2). In addition, 16 patients had dose reduction because of adverse events.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Treatment-emergent adverse events occurring in at least 10% of the patients.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">Events, <italic>n</italic> (%)</th><th align="left" valign="bottom" colspan="2">All (<italic>n</italic> = 141)</th></tr><tr><th align="left" valign="bottom">Any grade</th><th align="left" valign="bottom">Grade 3</th></tr></thead><tbody><tr><td align="left" valign="bottom">Diarrhea</td><td align="left" valign="bottom">112 (79.4%)</td><td align="left" valign="bottom">43 (30.5%)</td></tr><tr><td align="left" valign="bottom">Fatigue</td><td align="left" valign="bottom">52 (36.9%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Lymphocyte count decreased</td><td align="left" valign="bottom">52 (36.9%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Nausea</td><td align="left" valign="bottom">47 (33.3%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Hand-foot syndrome</td><td align="left" valign="bottom">47 (33.3%)</td><td align="left" valign="bottom">1 (0.7%)</td></tr><tr><td align="left" valign="bottom">Hyperuricemia</td><td align="left" valign="bottom">33 (23.4%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">White blood cell count decreased</td><td align="left" valign="bottom">26 (18.4%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Dizziness</td><td align="left" valign="bottom">26 (18.4%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Anemia</td><td align="left" valign="bottom">24 (17.0%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Vomiting</td><td align="left" valign="bottom">22 (15.6%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Headache</td><td align="left" valign="bottom">19 (13.5%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Creatinine increased</td><td align="left" valign="bottom">17 (12.1%)</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Neutrophil count decreased</td><td align="left" valign="bottom">16 (11.3%)</td><td align="left" valign="bottom">0</td></tr></tbody></table></table-wrap></sec></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>To the best of our knowledge, this multicenter phase II study is the first prospective study to explore the efficacy and safety of extended adjuvant pyrotinib after trastuzumab-based adjuvant therapy in patients with high-risk HER2-positive breast cancer. Furthermore, while the ExteNET study only included patients who received neoadjuvant or adjuvant trastuzumab, over one-third of the patients in our study had received dual anti-HER2 blockade with trastuzumab and pertuzumab, making it more clinically applicable to current clinical practice (<xref ref-type="bibr" rid="bib2">Bevers et al., 2023</xref>). In China, pertuzumab was approved for the treatment of HER2-positive breast cancer in the adjuvant setting in 2018, and has been covered by medical insurance since 2020. The PERSIST study started in 2019, thus the proportion of eligible patients who received trastuzumab and pertuzumab in our study was relatively high. In addition, we conducted subgroup analyses to explore the differences in the efficacy of extended adjuvant pyrotinib across different prior adjuvant regimens, including trastuzumab plus pertuzumab or trastuzumab alone, and different treatment durations.</p><p>Currently, only neratinib has been approved by Food and Drug Administration in the extended adjuvant setting for patients with HER2-positive early or locally advanced breast cancer. In the 2023 National Comprehensive Cancer Network guidelines, it has been recommended for the treatment of high-risk, HR-positive, HER2-positive breast cancer (<xref ref-type="bibr" rid="bib17">Nahta and O’Regan, 2012</xref>). In the ExteNET study, 1-year neratinib treatment after adjuvant trastuzumab significantly improved iDFS in patients with HER2-positive breast cancer, with a 2-year iDFS rate of 93.9% in the neratinib group and 91.6% in the placebo group (<xref ref-type="bibr" rid="bib16">Martin et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Burstein et al., 2021</xref>). In our study, the 2-year iDFS rate was 94.59%, comparable to that in the ExteNET study.</p><p>In terms of subgroup analyses, the HR-positive group seemed to show a numerically higher 2-year iDFS rate than the HR-negative group (96.74% vs 92.77%). Consistently, similar results were observed in the ExteNET study. The underlying mechanism may involve cross-talk between HR and HER2 pathways (<xref ref-type="bibr" rid="bib18">Pegram et al., 2023</xref>; <xref ref-type="bibr" rid="bib25">Sudhan et al., 2019</xref>). Preclinical studies have shown that in estrogen receptor+/HER2+ cell lines, neratinib treatment also suppresses the activity of estrogen reporter (<xref ref-type="bibr" rid="bib10">Hu et al., 2023</xref>). In the present study, adjuvant endocrine therapy was recommended for patients with HR-positive disease when treated with pyrotinib, which may generate synergistic effects (<xref ref-type="bibr" rid="bib31">Zhang et al., 2022</xref>; <xref ref-type="bibr" rid="bib21">Pivot et al., 2019</xref>).</p><p>Regarding duration of treatment, the results showed that the 2-year iDFS rate was numerically higher with 1-year pyrotinib treatment (94.90%) versus 6-month pyrotinib treatment (90.32%). In the adjuvant setting, a phase III PHARE trial compared 1-year adjuvant trastuzumab with 6-month treatment, and the non-inferiority was not achieved for disease-free survival. Therefore, 1-year adjuvant trastuzumab remained the standard treatment (<xref ref-type="bibr" rid="bib26">von Minckwitz et al., 2017</xref>). Further studies are warranted to find the optimal duration of extended adjuvant pyrotinib.</p><p>Adjuvant treatment regimens before extended adjuvant treatment may also be associated with iDFS. In the present study, the 2-year iDFS rate was 93.48% and 97.30% in the trastuzumab subgroup and trastuzumab plus pertuzumab subgroup, respectively. The APHINITY study demonstrated a significantly improved iDFS with adjuvant trastuzumab plus pertuzumab than with adjuvant trastuzumab alone (<xref ref-type="bibr" rid="bib27">von Minckwitz et al., 2019</xref>). Therefore, the iDFS benefits may last and affect the results in the extended adjuvant period.</p><p>None of the patients in the PERSIST study received trastuzumab emtansine (T-DM1), which is now a standard of care for HER2-positive patients with residual cancer after neoadjuvant therapy based on the phase III KATHERINE trial (<xref ref-type="bibr" rid="bib11">Liang et al., 2024</xref>). Since T-DM1 was approved in China in 2020 and was not covered by medical insurance until 2023, it has not been widely used in clinical practice. Recently, a real-world study showed that patients with metastatic breast cancer could benefit from pyrotinib-based therapy after T-DM1 treatment (<xref ref-type="bibr" rid="bib23">Shyam Sunder et al., 2023</xref>). Therefore, patients with high-risk breast cancer may also benefit from extended adjuvant pyrotinib after being treated with T-DM1 in the adjuvant setting, which needs further investigation.</p><p>Regarding adverse events, diarrhea was the major safety concern in the present study, leading to treatment discontinuation in eight patients. This adverse event as well as vomiting and nausea are TKI-related common adverse events. The underlying mechanisms of these adverse events are not clear yet, and the mainstream hypothesis is that the growth and healing of epithelial cells in gastrointestinal tract are inhibited by TKIs (<xref ref-type="bibr" rid="bib22">Secombe et al., 2020</xref>; <xref ref-type="bibr" rid="bib7">Guan et al., 2023a</xref>). In the present study, 43 (30.5%) patients experienced grade 3 diarrhea, which were consistent with previous studies of pyrotinib (<xref ref-type="bibr" rid="bib8">Guan et al., 2023b</xref>; <xref ref-type="bibr" rid="bib6">Fang et al., 2022</xref>). Noteworthy, primary prophylaxis was not mandatory in this PERSIST trial. Currently, loperamide hydrochloride has been found to significantly alleviate symptoms of diarrhea and reduce diarrhea-related treatment discontinuation. It has been recommended for patients treated with pyrotinib (<xref ref-type="bibr" rid="bib32">Zheng et al., 2023</xref>). In the PANDORA trial of pyrotinib plus docetaxel, the incidence of diarrhea was significantly lower in the loperamide prophylaxis group (8.9%) compared with the non-prophylaxis group (38.2%) (<xref ref-type="bibr" rid="bib1">Barcenas et al., 2020</xref>). In the CONTROL trial, all cohorts that received loperamide prophylaxis and the dose escalation cohort of neratinib exhibited lower grade 3 diarrhea rates and fewer instances of diarrhea-related treatment discontinuation compared with ExteNET (<xref ref-type="bibr" rid="bib1">Barcenas et al., 2020</xref>). The above two studies indicated that pyrotinib-related diarrhea could be controlled with prophylaxis or dose modification.</p><p>There are several limitations in the present study. First, our study was a single-arm study without control group. Second, patients who received T-DM1 therapy in the adjuvant setting were not enrolled. Third, 27.0% of patients did not complete 1-year extended adjuvant pyrotinib due to COVID-19 pandemic or personal reasons. Finally, the follow-up time was short. A phase III clinical trial (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03980054?cond=NCT03980054&amp;draw=2&amp;rank=1">NCT03980054</ext-link>) of extended adjuvant pyrotinib in patients with high-risk HER2-positive breast cancer is ongoing, which will further demonstrate the efficacy of extended adjuvant TKI and bring new hope for patients with high-risk HER2-positive breast cancer.</p><sec id="s4-1"><title>Conclusions</title><p>Our study suggests the potential of extended adjuvant pyrotinib in patients with high-risk HER2-positive early or locally advanced breast cancer after trastuzumab-based adjuvant therapy. The follow-up is ongoing to determine the long-term benefit of extended adjuvant pyrotinib.</p></sec><sec id="s4-2"><title>Clinical trial registration number</title><p>This trial was registered at <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> (NCT05880927).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Software, Formal analysis, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con5"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Software, Investigation, Project administration</p></fn><fn fn-type="con" id="con7"><p>Resources, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision</p></fn><fn fn-type="con" id="con10"><p>Resources, Methodology, Project administration</p></fn><fn fn-type="con" id="con11"><p>Software, Validation</p></fn><fn fn-type="con" id="con12"><p>Supervision, Validation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con13"><p>Supervision, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Software, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Supervision, Validation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Resources, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>registration NCT05880927.</p></fn><fn fn-type="other"><p>The study protocol was approved by the institutional ethics committee of Taizhou Hospital of Zhejiang Province and all other participating centers.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-101724-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Processed raw data (with all private patient information removed).</title></caption><media xlink:href="elife-101724-data1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data used in the manuscript (with all private patient information removed) is included with the article as Source Data File 1. This file contains all the data used for the tables and for generating the graphs and charts.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank all the patients who participated in this trial and their families, as well as the investigators and staff. We thank Yan Luo (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co, Ltd) for data interpretation and Yunning Yang (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co, Ltd) for medical writing assistance according to Good Publication Practice Guidelines.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barcenas</surname><given-names>CH</given-names></name><name><surname>Hurvitz</surname><given-names>SA</given-names></name><name><surname>Di Palma</surname><given-names>JA</given-names></name><name><surname>Bose</surname><given-names>R</given-names></name><name><surname>Chien</surname><given-names>AJ</given-names></name><name><surname>Iannotti</surname><given-names>N</given-names></name><name><surname>Marx</surname><given-names>G</given-names></name><name><surname>Brufsky</surname><given-names>A</given-names></name><name><surname>Litvak</surname><given-names>A</given-names></name><name><surname>Ibrahim</surname><given-names>E</given-names></name><name><surname>Alvarez</surname><given-names>RH</given-names></name><name><surname>Ruiz-Borrego</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>N</given-names></name><name><surname>Manalo</surname><given-names>Y</given-names></name><name><surname>Kellum</surname><given-names>A</given-names></name><name><surname>Trudeau</surname><given-names>M</given-names></name><name><surname>Thirlwell</surname><given-names>M</given-names></name><name><surname>Garcia Saenz</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>D</given-names></name><name><surname>Bryce</surname><given-names>R</given-names></name><name><surname>McCulloch</surname><given-names>L</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Tripathy</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><collab>CONTROL Study Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial</article-title><source>Annals of Oncology</source><volume>31</volume><fpage>1223</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.05.012</pub-id><pub-id pub-id-type="pmid">32464281</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bevers</surname><given-names>TB</given-names></name><name><surname>Niell</surname><given-names>BL</given-names></name><name><surname>Baker</surname><given-names>JL</given-names></name><name><surname>Bennett</surname><given-names>DL</given-names></name><name><surname>Bonaccio</surname><given-names>E</given-names></name><name><surname>Camp</surname><given-names>MS</given-names></name><name><surname>Chikarmane</surname><given-names>S</given-names></name><name><surname>Conant</surname><given-names>EF</given-names></name><name><surname>Eghtedari</surname><given-names>M</given-names></name><name><surname>Flanagan</surname><given-names>MR</given-names></name><name><surname>Hawley</surname><given-names>J</given-names></name><name><surname>Helvie</surname><given-names>M</given-names></name><name><surname>Hodgkiss</surname><given-names>L</given-names></name><name><surname>Hoyt</surname><given-names>TL</given-names></name><name><surname>Ivanovich</surname><given-names>J</given-names></name><name><surname>Jochelson</surname><given-names>MS</given-names></name><name><surname>Kulkarni</surname><given-names>S</given-names></name><name><surname>Lancaster</surname><given-names>RB</given-names></name><name><surname>Mauer</surname><given-names>C</given-names></name><name><surname>Maxwell</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>BK</given-names></name><name><surname>Pearlman</surname><given-names>M</given-names></name><name><surname>Philpotts</surname><given-names>L</given-names></name><name><surname>Plecha</surname><given-names>D</given-names></name><name><surname>Plichta</surname><given-names>JK</given-names></name><name><surname>Shakeri</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>ML</given-names></name><name><surname>Streibert</surname><given-names>CL</given-names></name><name><surname>Strigel</surname><given-names>RM</given-names></name><name><surname>Tumyan</surname><given-names>L</given-names></name><name><surname>Winkler</surname><given-names>NS</given-names></name><name><surname>Wolverton</surname><given-names>DE</given-names></name><name><surname>Bergman</surname><given-names>MA</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Stehman</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>NCCN guidelines insights: breast cancer screening and diagnosis, version 1.2023</article-title><source>Journal of the National Comprehensive Cancer Network</source><volume>21</volume><fpage>900</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2023.0046</pub-id><pub-id pub-id-type="pmid">37673117</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>HJ</given-names></name><name><surname>Curigliano</surname><given-names>G</given-names></name><name><surname>Thürlimann</surname><given-names>B</given-names></name><name><surname>Weber</surname><given-names>WP</given-names></name><name><surname>Poortmans</surname><given-names>P</given-names></name><name><surname>Regan</surname><given-names>MM</given-names></name><name><surname>Senn</surname><given-names>HJ</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><collab>Panelists of the St Gallen Consensus Conference</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021</article-title><source>Annals of Oncology</source><volume>32</volume><fpage>1216</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.06.023</pub-id><pub-id pub-id-type="pmid">34242744</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>D</given-names></name><name><surname>Piccart-Gebhart</surname><given-names>MJ</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Procter</surname><given-names>M</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>de Azambuja</surname><given-names>E</given-names></name><name><surname>Castro</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Untch</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Al-Sakaff</surname><given-names>N</given-names></name><name><surname>Lauer</surname><given-names>S</given-names></name><name><surname>McFadden</surname><given-names>E</given-names></name><name><surname>Leyland-Jones</surname><given-names>B</given-names></name><name><surname>Bell</surname><given-names>R</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Jackisch</surname><given-names>C</given-names></name><collab>Herceptin Adjuvant (HERA) Trial Study Team</collab></person-group><year iso-8601-date="2017">2017</year><article-title>11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial</article-title><source>Lancet</source><volume>389</volume><fpage>1195</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32616-2</pub-id><pub-id pub-id-type="pmid">28215665</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Delaloge</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>FA</given-names></name><name><surname>Moy</surname><given-names>B</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Harvey</surname><given-names>VJ</given-names></name><name><surname>Robert</surname><given-names>NJ</given-names></name><name><surname>Silovski</surname><given-names>T</given-names></name><name><surname>Gokmen</surname><given-names>E</given-names></name><name><surname>von Minckwitz</surname><given-names>G</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Chia</surname><given-names>SKL</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Gore</surname><given-names>I</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Harker</surname><given-names>G</given-names></name><name><surname>Masuda</surname><given-names>N</given-names></name><name><surname>Petrakova</surname><given-names>K</given-names></name><name><surname>Zotano</surname><given-names>AG</given-names></name><name><surname>Iannotti</surname><given-names>N</given-names></name><name><surname>Rodriguez</surname><given-names>G</given-names></name><name><surname>Tassone</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Bryce</surname><given-names>R</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><collab>ExteNET Study Group</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>The Lancet. Oncology</source><volume>17</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00551-3</pub-id><pub-id pub-id-type="pmid">26874901</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>C</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients</article-title><source>Annals of Palliative Medicine</source><volume>11</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.21037/apm-21-3978</pub-id><pub-id pub-id-type="pmid">35144412</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer</article-title><source>Signal Transduction and Targeted Therapy</source><volume>8</volume><elocation-id>118</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-023-01322-w</pub-id><pub-id pub-id-type="pmid">36935426</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lan</surname><given-names>B</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies</article-title><source>Biomarker Research</source><volume>11</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/s40364-023-00453-0</pub-id><pub-id pub-id-type="pmid">36803645</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>FA</given-names></name><name><surname>Moy</surname><given-names>B</given-names></name><name><surname>Delaloge</surname><given-names>S</given-names></name><name><surname>Chia</surname><given-names>SKL</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Silovski</surname><given-names>T</given-names></name><name><surname>Šeparović</surname><given-names>R</given-names></name><name><surname>Bashford</surname><given-names>A</given-names></name><name><surname>Zotano</surname><given-names>AG</given-names></name><name><surname>Denduluri</surname><given-names>N</given-names></name><name><surname>Patt</surname><given-names>D</given-names></name><name><surname>Gokmen</surname><given-names>E</given-names></name><name><surname>Gore</surname><given-names>I</given-names></name><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Masuda</surname><given-names>N</given-names></name><name><surname>Tomašević</surname><given-names>Z</given-names></name><name><surname>Petráková</surname><given-names>K</given-names></name><name><surname>DiPrimeo</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><collab>ExteNET Study Group</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>European Journal of Cancer</source><volume>184</volume><fpage>48</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2023.02.002</pub-id><pub-id pub-id-type="pmid">36898233</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>ZY</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name><name><surname>Ran</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ouyang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial</article-title><source>BMC Medicine</source><volume>21</volume><elocation-id>226</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-023-02943-2</pub-id><pub-id pub-id-type="pmid">37365596</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Gui</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Di</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Long-term outcome analysis of pyrotinib in patients with HER2-positive metastatic breast cancer and brain metastasis: a real-world study</article-title><source>The Oncologist</source><volume>29</volume><fpage>e198</fpage><lpage>e205</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyad228</pub-id><pub-id pub-id-type="pmid">37589217</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HER2-positive breast cancer</article-title><source>The Lancet</source><volume>389</volume><fpage>2415</fpage><lpage>2429</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32417-5</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lüftner</surname><given-names>D</given-names></name><name><surname>Tesch</surname><given-names>H</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Hartkopf</surname><given-names>AD</given-names></name><name><surname>Streicher</surname><given-names>S</given-names></name><name><surname>Resch</surname><given-names>A</given-names></name><name><surname>Genovese</surname><given-names>L</given-names></name><name><surname>Rosé</surname><given-names>C</given-names></name><name><surname>Valenti</surname><given-names>R</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study</article-title><source>European Journal of Cancer</source><volume>150</volume><fpage>268</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.03.045</pub-id><pub-id pub-id-type="pmid">33971386</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Ouyang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study</article-title><source>Journal of Clinical Oncology</source><volume>37</volume><fpage>2610</fpage><lpage>2619</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.00108</pub-id><pub-id pub-id-type="pmid">31430226</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Ouyang</surname><given-names>Q</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Geng</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Mo</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Nie</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><collab>PHILA Investigators</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial</article-title><source>BMJ</source><volume>383</volume><elocation-id>e076065</elocation-id><pub-id pub-id-type="doi">10.1136/bmj-2023-076065</pub-id><pub-id pub-id-type="pmid">37907210</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Holmes</surname><given-names>FA</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Delaloge</surname><given-names>S</given-names></name><name><surname>Moy</surname><given-names>B</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Minckwitz</surname><given-names>G</given-names></name><name><surname>Chia</surname><given-names>SKL</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Tomašević</surname><given-names>Z</given-names></name><name><surname>Denduluri</surname><given-names>N</given-names></name><name><surname>Šeparović</surname><given-names>R</given-names></name><name><surname>Gokmen</surname><given-names>E</given-names></name><name><surname>Bashford</surname><given-names>A</given-names></name><name><surname>Ruiz Borrego</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>SB</given-names></name><name><surname>Jakobsen</surname><given-names>EH</given-names></name><name><surname>Ciceniene</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Overkamp</surname><given-names>F</given-names></name><name><surname>Heijns</surname><given-names>JB</given-names></name><name><surname>Armstrong</surname><given-names>AC</given-names></name><name><surname>Link</surname><given-names>JS</given-names></name><name><surname>Joy</surname><given-names>AA</given-names></name><name><surname>Bryce</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Auerbach</surname><given-names>A</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Blair HA: pyrotinib: first global approval. drugs</article-title><source>The Lancet Oncology</source><volume>78</volume><fpage>1688</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1007/s40265-018-0997-0</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahta</surname><given-names>R</given-names></name><name><surname>O’Regan</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers</article-title><source>Breast Cancer Research and Treatment</source><volume>135</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s10549-012-2067-8</pub-id><pub-id pub-id-type="pmid">22527112</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pegram</surname><given-names>M</given-names></name><name><surname>Jackisch</surname><given-names>C</given-names></name><name><surname>Johnston</surname><given-names>SRD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer</article-title><source>NPJ Breast Cancer</source><volume>9</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.1038/s41523-023-00533-2</pub-id><pub-id pub-id-type="pmid">37258523</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>EA</given-names></name><name><surname>Romond</surname><given-names>EH</given-names></name><name><surname>Suman</surname><given-names>VJ</given-names></name><name><surname>Jeong</surname><given-names>JH</given-names></name><name><surname>Sledge</surname><given-names>G</given-names></name><name><surname>Geyer</surname><given-names>CE</given-names></name><name><surname>Martino</surname><given-names>S</given-names></name><name><surname>Rastogi</surname><given-names>P</given-names></name><name><surname>Gralow</surname><given-names>J</given-names></name><name><surname>Swain</surname><given-names>SM</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Colon-Otero</surname><given-names>G</given-names></name><name><surname>Davidson</surname><given-names>NE</given-names></name><name><surname>Mamounas</surname><given-names>E</given-names></name><name><surname>Zujewski</surname><given-names>JA</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831</article-title><source>Journal of Clinical Oncology</source><volume>32</volume><fpage>3744</fpage><lpage>3752</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.55.5730</pub-id><pub-id pub-id-type="pmid">25332249</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Procter</surname><given-names>M</given-names></name><name><surname>Fumagalli</surname><given-names>D</given-names></name><name><surname>de Azambuja</surname><given-names>E</given-names></name><name><surname>Clark</surname><given-names>E</given-names></name><name><surname>Ewer</surname><given-names>MS</given-names></name><name><surname>Restuccia</surname><given-names>E</given-names></name><name><surname>Jerusalem</surname><given-names>G</given-names></name><name><surname>Dent</surname><given-names>S</given-names></name><name><surname>Reaby</surname><given-names>L</given-names></name><name><surname>Bonnefoi</surname><given-names>H</given-names></name><name><surname>Krop</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>T-W</given-names></name><name><surname>Pieńkowski</surname><given-names>T</given-names></name><name><surname>Toi</surname><given-names>M</given-names></name><name><surname>Wilcken</surname><given-names>N</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Im</surname><given-names>Y-H</given-names></name><name><surname>Tseng</surname><given-names>LM</given-names></name><name><surname>Lueck</surname><given-names>H-J</given-names></name><name><surname>Colleoni</surname><given-names>M</given-names></name><name><surname>Monturus</surname><given-names>E</given-names></name><name><surname>Sicoe</surname><given-names>M</given-names></name><name><surname>Guillaume</surname><given-names>S</given-names></name><name><surname>Bines</surname><given-names>J</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Thomssen</surname><given-names>C</given-names></name><collab>APHINITY Steering Committee and Investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up</article-title><source>Journal of Clinical Oncology</source><volume>39</volume><fpage>1448</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.01204</pub-id><pub-id pub-id-type="pmid">33539215</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pivot</surname><given-names>X</given-names></name><name><surname>Romieu</surname><given-names>G</given-names></name><name><surname>Debled</surname><given-names>M</given-names></name><name><surname>Pierga</surname><given-names>JY</given-names></name><name><surname>Kerbrat</surname><given-names>P</given-names></name><name><surname>Bachelot</surname><given-names>T</given-names></name><name><surname>Lortholary</surname><given-names>A</given-names></name><name><surname>Espié</surname><given-names>M</given-names></name><name><surname>Fumoleau</surname><given-names>P</given-names></name><name><surname>Serin</surname><given-names>D</given-names></name><name><surname>Jacquin</surname><given-names>JP</given-names></name><name><surname>Jouannaud</surname><given-names>C</given-names></name><name><surname>Rios</surname><given-names>M</given-names></name><name><surname>Abadie-Lacourtoisie</surname><given-names>S</given-names></name><name><surname>Venat-Bouvet</surname><given-names>L</given-names></name><name><surname>Cany</surname><given-names>L</given-names></name><name><surname>Catala</surname><given-names>S</given-names></name><name><surname>Khayat</surname><given-names>D</given-names></name><name><surname>Gambotti</surname><given-names>L</given-names></name><name><surname>Pauporté</surname><given-names>I</given-names></name><name><surname>Faure-Mercier</surname><given-names>C</given-names></name><name><surname>Paget-Bailly</surname><given-names>S</given-names></name><name><surname>Henriques</surname><given-names>J</given-names></name><name><surname>Grouin</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>6 months versus 12 months of adjuvant trastuzumab in early breast cancer phare</article-title><source>Lancet</source><volume>393</volume><fpage>2591</fpage><lpage>2598</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)30653-1</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Secombe</surname><given-names>KR</given-names></name><name><surname>Van Sebille</surname><given-names>YZA</given-names></name><name><surname>Mayo</surname><given-names>BJ</given-names></name><name><surname>Coller</surname><given-names>JK</given-names></name><name><surname>Gibson</surname><given-names>RJ</given-names></name><name><surname>Bowen</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome</article-title><source>Integrative Cancer Therapies</source><volume>19</volume><elocation-id>1534735420928493</elocation-id><pub-id pub-id-type="doi">10.1177/1534735420928493</pub-id><pub-id pub-id-type="pmid">32493068</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shyam Sunder</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>UC</given-names></name><name><surname>Pokharel</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management</article-title><source>Signal Transduction and Targeted Therapy</source><volume>8</volume><elocation-id>262</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-023-01469-6</pub-id><pub-id pub-id-type="pmid">37414756</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cancer statistics, 2014</article-title><source>CA</source><volume>64</volume><fpage>9</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3322/caac.21208</pub-id><pub-id pub-id-type="pmid">24399786</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhan</surname><given-names>DR</given-names></name><name><surname>Schwarz</surname><given-names>LJ</given-names></name><name><surname>Guerrero-Zotano</surname><given-names>A</given-names></name><name><surname>Formisano</surname><given-names>L</given-names></name><name><surname>Nixon</surname><given-names>MJ</given-names></name><name><surname>Croessmann</surname><given-names>S</given-names></name><name><surname>González Ericsson</surname><given-names>PI</given-names></name><name><surname>Sanders</surname><given-names>M</given-names></name><name><surname>Balko</surname><given-names>JM</given-names></name><name><surname>Avogadri-Connors</surname><given-names>F</given-names></name><name><surname>Cutler</surname><given-names>RE</given-names></name><name><surname>Lalani</surname><given-names>AS</given-names></name><name><surname>Bryce</surname><given-names>R</given-names></name><name><surname>Auerbach</surname><given-names>A</given-names></name><name><surname>Arteaga</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER<sup>+</sup>/HER2<sup>+</sup> breast cancers: implications to the ExteNET trial</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>771</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1131</pub-id><pub-id pub-id-type="pmid">30274983</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Minckwitz</surname><given-names>G</given-names></name><name><surname>Procter</surname><given-names>M</given-names></name><name><surname>de Azambuja</surname><given-names>E</given-names></name><name><surname>Zardavas</surname><given-names>D</given-names></name><name><surname>Benyunes</surname><given-names>M</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Suter</surname><given-names>T</given-names></name><name><surname>Arahmani</surname><given-names>A</given-names></name><name><surname>Rouchet</surname><given-names>N</given-names></name><name><surname>Clark</surname><given-names>E</given-names></name><name><surname>Knott</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>I</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>Yardley</surname><given-names>DA</given-names></name><name><surname>Bines</surname><given-names>J</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><collab>APHINITY Steering Committee and Investigators</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer</article-title><source>The New England Journal of Medicine</source><volume>377</volume><fpage>122</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1703643</pub-id><pub-id pub-id-type="pmid">28581356</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Minckwitz</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>C-S</given-names></name><name><surname>Mano</surname><given-names>MS</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Mamounas</surname><given-names>EP</given-names></name><name><surname>Untch</surname><given-names>M</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name><name><surname>Rastogi</surname><given-names>P</given-names></name><name><surname>Schneeweiss</surname><given-names>A</given-names></name><name><surname>Redondo</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>HH</given-names></name><name><surname>Jacot</surname><given-names>W</given-names></name><name><surname>Conlin</surname><given-names>AK</given-names></name><name><surname>Arce-Salinas</surname><given-names>C</given-names></name><name><surname>Wapnir</surname><given-names>IL</given-names></name><name><surname>Jackisch</surname><given-names>C</given-names></name><name><surname>DiGiovanna</surname><given-names>MP</given-names></name><name><surname>Fasching</surname><given-names>PA</given-names></name><name><surname>Crown</surname><given-names>JP</given-names></name><name><surname>Wülfing</surname><given-names>P</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name><name><surname>Rota Caremoli</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lam</surname><given-names>LH</given-names></name><name><surname>Tesarowski</surname><given-names>D</given-names></name><name><surname>Smitt</surname><given-names>M</given-names></name><name><surname>Douthwaite</surname><given-names>H</given-names></name><name><surname>Singel</surname><given-names>SM</given-names></name><name><surname>Geyer</surname><given-names>CE</given-names><suffix>Jr</suffix></name><collab>KATHERINE Investigators</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Trastuzumab emtansine for residual invasive HER2-positive breast cancer</article-title><source>The New England Journal of Medicine</source><volume>380</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1814017</pub-id><pub-id pub-id-type="pmid">30516102</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>AC</given-names></name><name><surname>Hammond</surname><given-names>MEH</given-names></name><name><surname>Hicks</surname><given-names>DG</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Allison</surname><given-names>KH</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Bartlett</surname><given-names>JMS</given-names></name><name><surname>Bilous</surname><given-names>M</given-names></name><name><surname>Fitzgibbons</surname><given-names>P</given-names></name><name><surname>Hanna</surname><given-names>W</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name><name><surname>Mangu</surname><given-names>PB</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>EA</given-names></name><name><surname>Press</surname><given-names>MF</given-names></name><name><surname>Spears</surname><given-names>PA</given-names></name><name><surname>Vance</surname><given-names>GH</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><collab>American Society of Clinical Oncology</collab><collab>College of American Pathologists</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline update</article-title><source>Journal of Clinical Oncology</source><volume>31</volume><fpage>3997</fpage><lpage>4013</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.50.9984</pub-id><pub-id pub-id-type="pmid">24101045</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhen</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial</article-title><source>BMC Medicine</source><volume>20</volume><elocation-id>498</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-022-02708-3</pub-id><pub-id pub-id-type="pmid">36575513</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Ouyang</surname><given-names>Q</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>C</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><collab>PHOEBE Investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial</article-title><source>The Lancet. Oncology</source><volume>22</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30702-6</pub-id><pub-id pub-id-type="pmid">33581774</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Dalpiciclib combined with pyrotinib and letrozole in women with HER2-positive, hormone receptor-positive metastatic breast cancer (LORDSHIPS): a phase ib study</article-title><source>Frontiers in Oncology</source><volume>12</volume><elocation-id>775081</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.775081</pub-id><pub-id pub-id-type="pmid">35321427</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>WM</given-names></name><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>8314</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-44140-y</pub-id><pub-id pub-id-type="pmid">38097605</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101724.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yu</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College</institution><country>China</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>The study by Ma et al. provides <bold>fundamental</bold> findings and <bold>compelling</bold> evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial. The findings enhance the understanding of HER2-positive breast cancer. The claims are fully supported by the types of experiments that were performed.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101724.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This study introduces a novel therapeutic strategy for patients with high-risk HER2-positive breast cancer and demonstrates that the incorporation of pyrotinib into adjuvant trastuzumab therapy can improve invasive disease-free survival.</p><p>Strengths:</p><p>The study features robust logic and high-quality data. Data from 141 patients across 23 centers were analyzed, thereby effectively mitigating regional biases and endowing the research findings with high applicability.</p><p>Weaknesses:</p><p>(1) Introduction and Discussion: Update the literature regarding the efficacy of pyrotinib combined with trastuzumab in treating HER2-positive advanced breast cancer.</p><p>(2) Did all the data have a normal distribution? Expand the description of statistical analysis.</p><p>(3) The novelty and innovative potential of your manuscript compared to the published literature should be described in more detail in the abstract and discussion section.</p><p>(4) Figure legend should provide a bit more detail about what readers should focus on.</p><p>(5) P-values should be clarified for the analysis.</p><p>(6) The order (A, B, and C) in Figure 3 should be labeled in the upper left corner of the Figure.</p><p>Comments on revisions:</p><p>The authors responded well to my questions.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101724.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Feilin</given-names></name><role specific-use="author">Author</role><aff><institution>Zhejiang Taizhou Hospital</institution><addr-line><named-content content-type="city">Taizhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Zhaosheng</given-names></name><role specific-use="author">Author</role><aff><institution>Zhejiang Taizhou Hospital</institution><addr-line><named-content content-type="city">Taizhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Zenggui</given-names></name><role specific-use="author">Author</role><aff><institution>Zhejiang Taizhou Hospital</institution><addr-line><named-content content-type="city">Taizhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Weizhu</given-names></name><role specific-use="author">Author</role><aff><institution>Ningbo Medical Center Lihuili Hospital</institution><addr-line><named-content content-type="city">Ningbo</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ouchen</given-names></name><role specific-use="author">Author</role><aff><institution>The First Affiliated Hospital of Wenzhou Medical University</institution><addr-line><named-content content-type="city">Wenzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Binbin</given-names></name><role specific-use="author">Author</role><aff><institution>Zhejiang Taizhou Hospital</institution><addr-line><named-content content-type="city">Taizhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Xiaotao</given-names></name><role specific-use="author">Author</role><aff><institution>Jinhua Municipal Central Hospital</institution><addr-line><named-content content-type="city">Jinhua</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Hao</surname><given-names>Jing</given-names></name><role specific-use="author">Author</role><aff><institution>Yiwu Central Hospital</institution><addr-line><named-content content-type="city">Jinhua</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Xiaochun</given-names></name><role specific-use="author">Author</role><aff><institution>Ningbo Medical Center Lihuili Hospital</institution><addr-line><named-content content-type="city">Ningbo</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhanwen</given-names></name><role specific-use="author">Author</role><aff><institution>Ningbo Women and Children's Hospital</institution><addr-line><named-content content-type="city">Ningbo</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Deyou</given-names></name><role specific-use="author">Author</role><aff><institution>Zhejiang Taizhou Hospital</institution><addr-line><named-content content-type="city">Taizhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Qingjing</given-names></name><role specific-use="author">Author</role><aff><institution>Yiwu Maternity and Children Hospital</institution><addr-line><named-content content-type="city">Yiwu</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Wei</given-names></name><role specific-use="author">Author</role><aff><institution>Quzhou People's Hospital</institution><addr-line><named-content content-type="city">Quzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Dongbo</given-names></name><role specific-use="author">Author</role><aff><institution>The First Affiliated Hospital of Ningbo University</institution><addr-line><named-content content-type="city">Ningbo</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Shu</surname><given-names>Jingde</given-names></name><role specific-use="author">Author</role><aff><institution>Quzhou People's Hospital</institution><addr-line><named-content content-type="city">Quzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Jichun</given-names></name><role specific-use="author">Author</role><aff><institution>Sir Run Run Hospital</institution><addr-line><named-content content-type="city">Zhejiang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Shifen</given-names></name><role specific-use="author">Author</role><aff><institution>Zhejiang Taizhou Hospital</institution><addr-line><named-content content-type="city">Taizhou</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>This study introduces a novel therapeutic strategy for patients with high-risk HER2-positive breast cancer and demonstrates that the incorporation of pyrotinib into adjuvant trastuzumab therapy can improve invasive disease-free survival.</p><p>Strengths:</p><p>The study features robust logic and high-quality data. Data from 141 patients across 23 centers were analyzed, thereby effectively mitigating regional biases and endowing the research findings with high applicability.</p><p>Weaknesses:</p><p>(1) Introduction and Discussion: Update the literature regarding the efficacy of pyrotinib combined with trastuzumab in treating HER2-positive advanced breast cancer.</p></disp-quote><p>Thank you for this helpful suggestion. The literature regarding the efficacy of pyrotinib combined with trastuzumab in treating HER2-positive advanced breast cancer referenced in our manuscript was the PHILA study, but we mistakenly cited its corrections (reference 14). We revised this reference as suggested.</p><p>Changes in the text: Page 6, line 347-353.</p><disp-quote content-type="editor-comment"><p>(2) Did all the data have a normal distribution? Expand the description of statistical analysis.</p></disp-quote><p>As the sample size increases, the sampling distribution of the mean follows a normal distribution even when the underlying distribution of the original variable is non-normal, allowing the use of a normal distribution to calculate their confidence interval. We believe it is unnecessary to specifically describe whether the data followed a normal distribution in this study. Therefore, we did not revise the statistical section.</p><disp-quote content-type="editor-comment"><p>(3) The novelty and innovative potential of your manuscript compared to the published literature should be described in more detail in the abstract and discussion section.</p></disp-quote><p>Thank you for your suggestion. The word count for abstracts recommended by eLife is around 250 words. Therefore, we did not compare the present study with published literature in detail in the abstract, as this might exceed the recommended word limit. We revised the discussion section to provide a more detailed comparison between published literature and our study, and to analyze the novelty of our findings accordingly.</p><p>Changes in the text: Page 11, line 177-180.</p><disp-quote content-type="editor-comment"><p>(4) Figure legend should provide a bit more detail about what readers should focus on.</p></disp-quote><p>Thank you for this suggestion. We did not revise the figure legend of Figure 1, as it provides a common description. For the figure legend of Figure 2, we added the method used to estimate the invasive disease-free survival curve. For the figure legend of Figure 3, we added more details regarding methods and numbers of patients in different subgroups.</p><p>Changes in the text: Page 7, line 463-472.</p><disp-quote content-type="editor-comment"><p>(5) P-values should be clarified for the analysis.</p></disp-quote><p>Thank you for this comment. All subgroup analyses were post-hoc and lacked predefined hypotheses. Kaplan-Meier curves were used to present the subgroup results with the aim of performing descriptive statistics rather than inferential statistics. Therefore, we did not calculate their p-values.</p><disp-quote content-type="editor-comment"><p>(6) The order (A, B, and C) in Figure 3 should be labeled in the upper left corner of the Figure.</p></disp-quote><p>Thanks for this comment. We revised Figure 3 accordingly.</p><p>Changes in the text: Figure 3.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>In this manuscript, Cao et al. evaluated the efficacy and safety of 12 months pyrotinib after trastuzumab-based adjuvant therapy in patients with high-risk, HER2-positive early or locally advanced breast cancer. Notably, the 2-year iDFS rate reached 94.59% (95% CI: 88.97-97.38) in all patients, and 94.90% (95% CI: 86.97-98.06) in patients who completed 1-year treatment of pyrotinib. This is an interesting and uplifting results, given that in ExteNET study, the 2-year iDFS rate was 93.9% (95% CI 92·4-95·2) in the 1-year neratinib group, and the 5-year iDFS survival was 90.2%, and 1-year treatment of neratinib in ExteNET study did not translate into OS benefit after 8-year follow-up. In this case, readers will be eagerly anticipating the long-term follow-up results of the current PERSIST study, as well as the results of the phase III clinical trial (NCT03980054).</p><p>I have the following comments:</p><p>(1) The introduction of the differences between pyrotinib and neratinib in terms of mechanism, efficacy, resistance, etc. is supposed to be included in the text so that authors could better highlight the clinical significance of the current trial.</p></disp-quote><p>Thanks for this comment.</p><p>In terms of mechanism, pyrotinib and neratinib are both irreversible pan-HER tyrosine kinase inhibitors that target HER1, HER2 and HER4 by covalently binding to ATP binding sites. Overall, the similarities between them far outweigh the differences. This is the reason why we referenced the ExteNET study, which used neratinib as extended adjuvant therapy, for the sample size calculation.</p><p>Regarding efficacy, currently, no head-to-head studies comparing efficacy of pyrotinib and neratinib have been reported, and the comparison of the efficacy between them using historical data from different studies have inevitable bias due to differences in treatment regimens, study populations, assessment criteria, etc.</p><p>Regarding resistance, only a few studies with small sample size and case reports have investigated their mechanisms of resistance, and the underlying mechanisms have not been fully understood.</p><p>Collectively, we believe that the similarities in the mechanisms of these two drugs far outweigh their differences, and their efficacy and resistance cannot be reasonably compared. Moreover, the sample size calculation was conducted based on the premise that the two drugs are similar. After careful consideration, we believe that overanalyzing the differences between neratinib and pyrotinib would shift the focus of this manuscript. Therefore, we did not discuss their differences in the article.</p><disp-quote content-type="editor-comment"><p>(2) Please make sure that a total of 141 patients were enrolled in the study, 38 patients had a treatment duration of less than or equal to 6 months, and a total of 92 and 31 patients completed 1-year and 6-month treatment of extended adjuvant pyrotinib, respectively, which means 7 patients had a treatment duration of fewer than 6 months.</p></disp-quote><p>Thank you for raising this relevant question. There were 141 patients enrolled in the study and received study treatment, and a total of 92 and 31 patients completed 1-year and 6-month treatment of extended adjuvant pyrotinib. Of the remaining 18 patients, 16 patients had a treatment duration of fewer than 6 months, and 2 patients had a treatment duration longer than 6 months but less than 1 year.</p><disp-quote content-type="editor-comment"><p>(3) The previous surgery history should be provided, and how many patients received lumpectomy, and mastectomy.</p></disp-quote><p>Thank you for your suggestion. All patients in the present study underwent breast cancer surgery. Unfortunately, we did not collect data on the specific types of surgeries performed.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewing Editor:</bold></p><p>I have carefully reviewed the content and findings of your study, and while I recognize the potential impact of your research, there are several critical aspects that need to be addressed to fully appreciate the contribution of your work.</p><p>Significance of Findings:</p><p>Your study provides valuable insights into the efficacy and safety of pyrotinib as an extended adjuvant therapy following trastuzumab-based treatment in patients with high-risk HER2-positive breast cancer. The 2-year invasive disease-free survival (iDFS) rate of 94.59% is notably high and suggests that pyrotinib could be a promising option for patients who have completed trastuzumab therapy. This is particularly significant given the unmet need for effective therapies that can extend disease-free survival in this patient population.</p><p>Strength of Evidence:</p><p>The strength of the evidence presented is supported by the multicenter phase II trial design, which included a substantial number of patients across 23 centers in China. The rigorous methodology, including the use of the Kaplan-Meier method for estimating iDFS and the application of the Brookmeyer-Crowley method for confidence intervals, adds to the credibility of your findings. However, the single-arm study design without a control group limits the ability to draw definitive conclusions about the comparative effectiveness of pyrotinib.</p><p>In conclusion, your study presents intriguing findings that contribute to the field of breast cancer therapy. However, the current evidence, while suggestive of pyrotinib's potential, requires further validation in controlled trials to confirm its efficacy and optimal use in clinical practice. I encourage you to address the issues raised and consider resubmitting a revised version of your work.</p></disp-quote><p>Thank you for your comments. We acknowledge the limitation of our single-arm study design without a control group and agree that it restricts definitive conclusions about the comparative effectiveness of pyrotinib. This limitation was noted in our manuscript. Furthermore, we have revised our manuscript in response to the issues raised by the reviewers.</p></body></sub-article></article>